Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574579 | 0.91 | PSMB1 (0.70) | HRH3 | |
| SCHEMBL3581930 | 0.91 | HRH3 (0.89) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL3578343 | 0.89 | PSMB1 (0.67) | HRH3 | |
| SCHEMBL3578646 | 0.87 | HRH3 (0.90) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL4094339 | 0.86 | HRH3 (1.00) | HRH3KCNH2HRH1 | |
| SCHEMBL12050645 | 0.86 | HRH3 (1.00) | HRH3KCNH2HRH1 | |
| SCHEMBL23804894 | 0.84 | HRH3 (0.77) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL12050718 | 0.84 | HRH3 (0.96) | HRH3KCNH2HRH1 | |
| SCHEMBL491825 | 0.83 | HRH3 (1.00) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL492096 | 0.83 | HRH3 (1.00) | HRH3KCNH2ACHERAD52HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | HRH3 2899/4885KCNH2 3956/4885ACHE 3395/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | HRH3 3666/4885KCNH2 3583/4885ACHE 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.